Abstract-Statin therapy has delivered tremendous value to society by improving the burden of atherosclerotic cardiovascular disease. Nonetheless, atherosclerotic cardiovascular disease remains the leading cause of death globally. Technological advances such as in the field of genomics have revolutionized drug discovery and development and have revealed novel therapeutic targets to lower low-density lipoprotein cholesterol (LDL-C), as well as other detrimental lipids and lipoproteins. Therapeutic LDL-C lowering prevents atherosclerotic cardiovascular disease with an effect size proportional to absolute LDL-C reductions and time of exposure. This understanding supports the notion that reducing cumulative LDL-C exposure should be a key therapeutic target. PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibiting monoclonal antibodies provides the possibility of reducing LDL-C to very low levels. Novel therapeutic platforms such as RNA inhibition present opportunities to combine robust lipid lowering with infrequent dosing regimens, introducing therapies with vaccine-like properties. 
A therosclerotic cardiovascular disease (ASCVD) is the leading cause of death globally. 1 Since 2015, ASCVD has affected upward of 40% of Americans, and total costs have accumulated to $555 billion in 2016. Without societywide interventions, this figure is projected to exceed $1 trillion by 2035. 2 Established lipid-lowering therapies, predominantly statins, have delivered tremendous clinical and societal value by lowering low-density lipoprotein cholesterol (LDL-C), thereby preventing ASCVD and mortality. 3 Although LDL-C is the dominant risk factor for ASCVD, currently available lipid-lowering therapies are insufficient to bring a halt to the ASCVD epidemic for several reasons. First, side effects preclude a substantial proportion of individuals from receiving adequate doses. 4 Second, adherence to statin therapy is generally poor (eg, especially with intensive dosing regimens). 5 Third, the efficacy of statins is limited: even high-intensity statin therapy in combination with ezetimibe would leave up to a sixth of patients in need of additional lipid lowering. 6, 7 Fourth, although a new effective option has recently become available in the form of therapeutic mAb (monoclonal antibody) inhibitors of PCSK9 (proprotein convertase subtilisin/kexin type 9), most patients who need additional lipid lowering are unable to receive PCSK9 inhibiting mAbs because of high cost and significant injection burden. 8 Thus, there is an enormous unmet need for effective and accessible lipid-lowering therapies. Recent years have witnessed tremendous progress, and several promising therapies are currently in early-and late-stage clinical development. This review addresses these latest therapeutic developments, focusing on their mechanisms, efficacy, and safety (Table) .
Please see https://www.ahajournals.org/atvb/atvbfocus for all articles published in this series.
Low-Density Lipoprotein
Plasma LDL (low-density lipoprotein) particles are formed after hydrolysis of triglycerides from liver-derived VLDL (very low-density lipoprotein) by LPL (lipoprotein lipase) in skeletal muscle for beta-oxidation ( Figure 1 ). LDL particles are cleared by the liver through receptor-mediated endocytosis in clathrin-coated pits, with the LDLR (LDL Patients with familial hypercholesterolemia (FH) have inadequate clearance of LDL particles, most commonly due to mutations in LDLR, APOB, or PCSK9. These patients are at higher risk for premature ASCVD 9 unless their LDL-C is pharmacologically lowered. Genome-wide association studies [10] [11] [12] [13] and Mendelian randomization studies 7, 14 of genetic variants affecting LDL particles also showed more ASCVD with higher LDL-C.
Clinical trials with 4 classes of LDL-C-lowering drugs have consolidated the beneficial effect of LDL-C lowering on ASCVD risk. First, the bile acid sequestrant cholestyramine was shown to reduce coronary heart disease (CHD). 15 Second, statins have been proven over and over again to prevent cardiovascular events across populations, both in low-and high-risk individuals. 16 Ezetimibe, an inhibitor of intestinal and biliary cholesterol absorption via NPC1L1, was recently shown to enhance transintestinal cholesterol excretion as well. 17 19, 20 In many patients, especially those with ASCVD, statins are unable to reduce LDL-C to levels that are proposed by clinical treatment guidelines. 21 This may be due to the severity of the hypercholesterolemia, such as in FH, or due to side effects at higher doses of statins, most often related to myalgias.
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PCSK9 inhibitors have the potential to address much of this unmet clinical need. They were developed upon the discovery that PCSK9 promotes degradation of the LDLR, see Figure 2 . This discovery was based on observations in patients, with gain of function mutations in PCSK9 showing elevated LDL-C and more ASCVD, as well as families with loss of function mutations in PCSK9 having reduced LDL-C and less ASCVD. 23, 24 
PCSK9 Inhibition
Initial strategies to reduce plasma PCSK9 involved mAbs. To date, 2 mAbs are approved for clinical use: evolocumab and alirocumab 25, 26 ( Figure 2 ). Numerous studies have shown powerful LDL-C lowering of ≈50% to 60% in various patient groups, regardless of the use of background statins, and including patients with FH. 27 As mentioned above, both PCSK9-mAbs were recently shown to reduce ASCVD events in large-scale outcomes trials. Evolocumab reduced the composite end point of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina or coronary revascularization myocardial infarction, stroke, and coronary revascularization by 13.2% in a secondary prevention population, and alirocumab provided a 14.4% major adverse cardiac event reduction in a population with recent acute coronary syndrome. 18 In a prespecified analysis of the FOURIER 28 Taken together, PCSK9-mAbs have a very beneficial drug profile, which has already led to changes in practice in lipid clinics, especially for patients with FH. Unfortunately, the cost of PCSK9-mAb therapy and related reimbursement hurdles have prevented the use of these drugs for a significant proportion of FH patients.
Small interfering (si)RNA represents a novel therapeutic platform to harness the natural mechanism of RNA interference to inhibit protein synthesis ( Figure 2 ). Inclisiran is an investigational small interfering RNA inhibitor of PCSK9 that is currently in phase III development. It comprises a duplex RNA backbone linked to triantennary N-acetylgalactosamine for liver-directed delivery. Chemical modifications to the backbone render the molecule resistant to endo-and terminal nucleases and ensure that inclisiran does not elicit immunogenic reactions (a significant issue for RNA therapeutics in the past). 29 The phase II ORION-1 trial (Inclisiran for Subjects With ACSVD or ACSVD-Risk Equivalents and Elevated Low-Density Lipoprotein Cholesterol) included 501 individuals at high ASCVD risk and with elevated LDL-C despite optimized statin therapy. A starting regimen of inclisiran 300 mg at day 1 and day 90 reduced plasma PCSK9 up to 70% and lowered LDL-C by 52.6% after 6 months. 21 Time-averaged LDL-C reductions were still >50% at day 270 (6 months after the final injection), supporting a 2-yearly maintenance regimen which is currently being evaluated in phase III registration studies. 30 Of note, all ORION-1 participants in the 300 mg two-dose group responded, with modest interindividual response variation. Inclisiran was generally well-tolerated in ORION-1, ≈2000 patient-years of data collected to date have not revealed material safety findings. 31 Inclisiran thus has a predictable and substantial LDL-C-lowering effect, and the infrequent dosing regimen could significantly improve therapy adherence. An ASCVD outcomes trial including ≈15 000 patients (ORION-4) has started enrolling patients in late 2018. Inclisiran is expected to become available for patients in early 2021.
Active immunization represents another strategy to inhibit PCSK9 ( Figure 2) . In murine models, the vaccine AT04 showed lipid-lowering 32, 33 and antiatherosclerotic effects, 32 with a mean LDL-C reduction of 13.3% at week 70.
32 It remains to be determined whether modifications in vaccine formulation or dosing regimens could potentially increase the achieved LDL-C reductions and prolong the duration of effect.
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Gene editing represents a third promising method to produce durable inhibition of PCSK9. Murine models showed promising preliminary findings, although off-target mutagenesis remains a concern of gene editing in general.
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Gemcabene: Acetyl-CoA Carboxylase Inhibitor ACC (acetyl-CoA carboxylase) inhibitor (gemcabene) is a dicarboxylic acid that reduces the production of hepatic triglycerides and cholesterol and enhances the clearance of VLDL cholesterol. The mode of action is not fully understood but possibly includes inhibition of ACC, HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) synthase, and a reduction of apoCIII (apolipoprotein-CIII) levels. Phase II trials in patients with low high-density lipoprotein cholesterol (HDL-C), 35 mixed hyperlipidemia, 36 and heterozygous and homozygous FH 37 did reveal reductions in apoB (apolipoprotein B)-containing lipoproteins and showed favorable tolerability and safety. Specifically, LDL-C reductions varied between 13% and 28%. 36, 38 Indeed, ACC inhibition may reduce toxic intermediates of triglycerides synthesis that inhibit fatty acid oxidation and thus exacerbate hepatic steatosis in nonalcoholic steatohepatitis. 39 However, the development of gemcabene is delayed due to a partial clinical hold concerning studies >6 months of duration issued by the US Food and Drug Administration because of the potential PPAR (peroxisome proliferator-activated receptor alpha)-like properties of the drug. 40 Gemphire illustrated in a 2-year rodent carcinogenicity study that the PPARα receptor interaction of gemcabene illustrated a potential rodent-specific tumorigenesis in the liver, as observed with gemfibrozil. In the meantime, Gemphire will continue their phase II POC trial and evaluate the "End of Trial"outcomes jointly with the US Food and Drug Administration to design the projected phase III trial for gemcabene. Importantly, gemcabene could be a potentially valuable therapy particularly for patients with homozygous FH because it lowers LDL-C independently of LDLR functionality.
Bempedoic Acid: ATP-Citrate Lyase Inhibitor
ETC-1002 (bempedoic acid) is an orally and once daily administered drug that simultaneously inhibits ACL (ATPcitrate lyase) and activates AMpK (AMP-activated protein kinase). This reduces hepatic cholesterol synthesis and increases LDLR expression. AMpK activation also reduces inflammation, which may offer additional cardiometabolic protection. 41 Bempedoic acid is only metabolized to its active form in the liver and not in muscle, which is of potential benefit to patients with statin intolerance. Phase II trial including statin-intolerant patients and in addition to PCSK9 inhibition showed significant LDL-C lowering of up to 24% and favorable tolerability. [42] [43] [44] A phase III ASCVD outcome trial is ongoing (CLEAR-OUTCOMES [Evaluation of Major Cardiovascular 
MGL-3196: Thyroid Receptor Beta Agonists
Selective thyromimetics lower apoB-containing particles by increasing LDLR in an HMGCR-independent fashion and by inhibiting SREBP-1c (sterol regulatory element-binding transcription factor 1c). 45 In rodent studies, thyromimetics induced CYP7A1 (cholesterol 7 alpha-hydroxylase), the rate-limiting enzyme in the conversion of cholesterol into bile acids, although data are conflicting as to whether CYP7A1 is induced in humans. 45 The selective thyroid receptor beta agonist eprotirome lowered LDL-C concentrations in a phase III trial of patients with heterozygous FH when added to conventional statin treatment with or without ezetimibe, but it also induced significant elevations of serum transaminases, indicating hepatotoxicity. These findings, along with findings of cartilage damage in dogs, led to discontinuation of eprotirome as a lipid-lowering drug. 46 Another thyromimetic, VK2809 (or MB07811), showed more favorable liver safety in a phase II trial. 47 This trial included patients with hypercholesterolemia and nonalcoholic fatty liver disease, in which 12 weeks of treatment resulted in a 20% LDL-C reduction, with a significant reduction in apoB and Lp(a) [lipoprotein(a)]. Moreover, 77% to 90% of included patients experienced >30% reduction in liver steatosis relative to placebo, averaging 57% liver fat reduction, assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF). 48 Finally, in 2016, a phase II trial by Madrigal administered liver-specific thyroid receptor beta agonist, MGL-3196, to patients successfully. They included 125 biopsy-confirmed nonalcoholic steatohepatitis patients in a randomized controlled trial (RCT) and illustrated that MGL-3196 lowered LDL-C significantly by 19% to 21% relative to placebo and up to 28.5% in patients intolerant to statin treatment. Also, apoB, TG (25%-31%), apoCIII, and Lp(a) (25%-40%), were reduced by MGL-3196 treatment. 
Obicetrapib: CETP Inhibitors
CETP (cholesteryl ester transfer protein) inhibitors can reduce LDL-C and raise HDL-C by inhibiting cholesterol-ester transfer from HDL (high-density lipoprotein) particles to LDL particles ( Figure 1 ). CETP inhibitors were initially developed based on the presumption that increasing HDL-C levels would improve clinical outcomes. However, Mendelian randomization studies and the results of trials of CETP inhibitors demonstrated that the benefit of reduced CETP activity is driven by reductions in apoB-containing particles rather than by increasing HDL-C. In 2017, the REVEAL trial (Randomized Evaluation of the Effects of Anacetrapib Through LipidModification) of anacetrapib delivered proof-of-concept that CETP inhibition reduces the risk of cardiovascular events through lowering of apoB.
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Figure 2. Regulation of LDL (low-density lipoprotein)-particle clearance mediated by PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition through mAb (monoclonal antibody) and ASO (antisense oligonucleotide)/siRNA (short inhibiting RNA).
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Interestingly, in patients who are already on a statin, CETP inhibition reduces apoB disproportionately less than it reduces LDL-C. On the contrary, statin naïve patients have an apoB reduction that is proportionate to the LDL-C reduction. 51 The mechanism behind this interaction is currently unknown. Since apoB is a stronger marker of ASCVD than LDL-C, this disproportionality may explain the lack of CV benefit from CETP inhibitors, when assessed on top of statins. Strong support for this hypothesis came from a recent sizable Mendelian randomization study of variances in the CETP gene and the gene encoding HMG-CoA reductase, the target of statins. Variance in CETP alone was associated with a proportionate variation in apoB and LDL-C, and reduced CETP activity was associated with reduced risk for ASCVD. When adding variance of HMGCR into the equation, an identical disproportion between apoB reduction and LDL-C reduction occurred as in the CETP inhibitor trials, and indeed the atheroprotective effect of reduced CETP activity was significantly reduced. 52 This may indicate that CETP inhibitors are of interest to patients with statin intolerance. Estimates of statin-intolerant patients with an indication for lipid-lowering range from 5 to 13 million in North America 53 to 16 million in Europe. 52, 54 The last CETP inhibitor currently assessed, obicetrapib (TA-8995), showed promising results as it reduced LDL-C up to 45.3% after 12 weeks when compared to placebo as monotherapy. 51 Phase III studies of obicetrapib in statin-intolerant patients are currently in the planning phase.
Homozygous FH
In the homozygous form of FH-prevalence 1: 160 000 to 300 000-statins and PCSK9 inhibitors are less effective because no or only defective LDLR may be present. 55 Two alternative approaches are available to treat homozygous FH: MTTP (microsomal triglyceride transfer protein) inhibition and antisense apoB. Both reduce hepatic VLDL production, rather than enhance LDLR acivity. 56 Additionally, a PPARδ (peroxisome proliferator-activated receptor delta) agonist and an mAb for ANGPTL3 (angiopoietin-like protein 3; evinacumab) are evaluated as additional potential therapy for homozygote FH patients.
Lomitapide: Microsomal Triglyceride Transferring Protein Inhibitor
Lomitapide inhibits microsomal triglyceride transferring protein and consequently the lipidation of chylomicrons and VLDL particles with triglycerides ( Figure 3 ). This reduces apoB-containing lipoproteins in plasma, yet may induce intestinal lipid retention and hepatosteatosis. Nonetheless, lomitapide was approved for the treatment of homozygous FH after an open-label, single arm, phase III study, which enrolled 29 patients with homozygous FH. Lomitapide was administered on top of statin, with doses ranging from 5 to 60 mg daily. Mean LDL-C reduction was 50% after 26 weeks and 38% in the patients who completed 78 weeks of treatment. Most prevalent adverse effects were gastrointestinal complaints (27 out of 29 participants, reduced with low-fat diet), hepatic steatosis (liver fat content increased from 1.0% at baseline to 8.6%), and elevated alanine transaminase levels in 4 participants, which resolved upon dose reduction.
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Mipomersen: ASO Targeting ApoB
The antisense oligonucleotide (ASO) mipomersen targets hepatic apoB100 mRNA for degradation, thus reducing apoB production and VLDL secretion (Figure 3) . It reduced LDL-C by 25% to 30% in several phase III trials with FH patients and statin-intolerant patients, yet also induced hepatic steatosis, which limited its approval to the most severe FH patients, that is, homozygous FH.
58,59
MBX-8025: PPARδ Agonist
PPARδ augments fatty acid oxidation in skeletal muscle, liver, and white adipose tissue and enhances hepatic glucose metabolism and pancreatic β cell function. PPARδ activation decreases fatty acids, triglycerides, and LDL-C and increases HDL. 60 MBX-8025 is a potent PPARδ agonist that decreased LDL-C in subjects with mixed hyperlipidemia and animal models of homozygous FH. In a recent phase II trial, 13 homozygous FH patients were treated for 12 weeks, of which 8 were on LDL-C apheresis; none received lomitapide, mipomersen, or a PCSK9 inhibitor. Mean LDL-C reduction was 10%. MBX-8025 was generally well tolerated.
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Evinacumab and ASO Targeting ANGPTL3
ANGPTL3 inhibits LPL activity and thus the hydrolysis of TGs 62,63 ( Figure 1 ). GWAS indicated that genetic variants of ANGPTL3 are associated with plasma TG levels and LDL-C levels. 64 Additionally, patients with compound heterozygous nonsense mutations had a pan-hypolipidemia, with a clear gene-dose effect. 65 ANGPTL3 inhibitors are potentially useful therapies especially for patients with homozygous FH without residual LDLR activity because they lower LDL-C independently of the LDLR. In a study of 9 homozygous FH patients on conventional lipid-lowering therapy, evinacumab (a mAb for ANGPTL3), gave an additional reduction of LDL-C and TG of 49% and 47%, respectively. 66 In addition, the triglyceride-lowering effect of ANGPTL3 inhibitors could be of therapeutic value for patients with severe hypertriglyceridemia. A phase I study in healthy volunteers with an ANGPTL3 ASO reduced TGs by 63% and LDL-C by 33% in a dose-dependent manner. 67 Similar results were obtained with evinacumab, 68 which is currently under evaluation in several trials, including a phase III trial for homozygous FH and a study including patients with persistent hypercholesterolemia (heterozygous FH and non-heterozygous FH; URL: http://www.clinicaltrials.gov. Unique identifiers: NCT03399786, NCT03409744, NCT03175367).
Lipoprotein(a)
Lp(a) is a complex of normal LDL-C with the specific glycoprotein apo(a) [apolipoprotein(a)] linked to apoB-100 ( Figure 2 ). Approximately 20% of the population has high plasma Lp(a) levels, and evidence has accumulated that high Lp(a) is an independent risk factor for myocardial infarction, ischemic heart disease, and aortic valve stenosis. [69] [70] [71] In the Copenhagen City Heart Study, Lp(a) came forward as independent risk factor in both men and women over 10 years of follow up of 9330 individuals. 69 Furthermore, in a prospective group of >40 000 individuals in Denmark, the risk of myocardial infarction increased with Lp(a) concentrations. 71 Additional strong evidence of a causal relationship of Lp(a) with CVD comes from Mendelian randomization studies first published by Uterman et al. 72 Proposed atherogenic properties of Lp(a) are its affinity for oxidized phospholipids and endothelial proteoglycans, its antifibrinolytic effects and, indirectly, stimulation of smooth muscle cell proliferation.
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ASO Targeting Lp(a)
Several Lp(a)-lowering therapies are currently in development, including apo(a) synthesis inhibitors. Viney et al 74 evaluated an N-acetylgalactosamine-conjugated apo(a) antisense, reducing Lp(a) serum levels up to 92%. Twenty percent of participants experienced injection-site irritation and occasional flu-like symptoms, yet no other major adverse events occurred. 74 This year, Akcea announced positive results with significant dose-dependent reduction of Lp(a) from their phase II trial. 75 Upcoming trials will be able to test the effect of an isolated Lp(a)-lowering therapy on cardiovascular outcomes.
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Triglycerides
Hypertriglyceridemia was independently associated with ASCVD in several epidemiological studies, [77] [78] [79] and recent genetics studies pointed toward a causal relationship. Common variants associated with TG levels were significantly associated with CHD even after accounting for their effects on LDL-C and HDL-C. 79 A common gain-of-function variant in LPL is associated with a significant decrease in TG levels and also in CHD. 80 Carriers of loss-of-function variants of apoCIII, an inhibitor of LPL and hepatic uptake of TRLs (triglyceriderich lipoprotein), had reduced TG levels and reduced CHD. 81 Patients with premature atherosclerosis had a higher prevalence of mutations in APOA5, encoding the protein apoA-V, an activator of LPL and known modulator of triglyceride metabolism. 82 Thus, genetic studies strongly support a causal role in ASCVD for factors around LPL that regulate TRLs.
In contrast to genetic studies, RCTs with triglyceridelowering agents had thus far failed to support the causality of the relation between TRLs and ASCVD. These trials, mostly conducted in patients with type 2 diabetes mellitus, were not primarily powered on hypertriglyceridemia. Subanalyses of the patients with highest TGs in 2 prominent trials with fibrates, FIELD and ACCORD, indicated reduced CVD. 83, 84 This lends support to the causality of the relation between TRLs and ASCVD, yet a definitive answer from RCTs is still awaited. To this end, multiple ASCVD outcome studies with triglyceride-lowering agents in patients specifically selected for hypertriglyceridemia are underway. These trials will likely provide an answer to this major question in the field. Indeed, very recent data of a trial with eicosapentaenoic acid, discussed below, might suggest that this answer will be positive.
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Pemafibrate: Selective PPARα Modulator
The selective PPAR alpha modulator pemafibrate proved superior to fenofibrate regarding the TG-lowering effect and hepatic and renal safety. 85 It is now assessed in a cardiovascular outcomes trial: the PROMINENT study, in patients with diabetes mellitus type 2 and diabetic dyslipidemia, with triglycerides between 200 and 500 mg/dl (URL: http://www. clinicaltrials.gov. Unique identifier: NCT03071692).
Eicosapentaenoic Acid: Fish Oils
Fish oils have been reported to have beneficial effects on multiple atherosclerotic processes, including endothelial function, oxidative stress, foam-cell formation, inflammation, plaque formation and rupture, platelet aggregation, and thrombus formation. 86 They also improve atherogenic dyslipidemia by reducing TG levels and remnant cholesterol without raising LDL-C levels in patients with very high TG levels 87 and in statin-treated patients with high TG levels and high residual CV risk. 88 Eicosapentaenoic acid was assessed in the cardiovascular outcome trial REDUCE-IT ([Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial] NCT01492361). It enrolled ≈8000 patients to receive either icosapent ethyl or placebo. Icosapent ethyl is a highly purified ethyl ester of eicosapentaenoic acid. It was evaluated whether icosapent ethyl, in patients who achieved guidelinedirected LDL-C target levels on statin therapy, was superior to statin therapy alone in reducing long-term cardiovascular events in high-risk patients with mixed dyslipidemia. Late September 2018, results of the REDUCE-IT trial revealed that the use of eicosapentaenoic acid led to a relative risk reduction of 25% for CV events. Thus, icosapent ethyl could be a valuable addition to optimized LDL-C-lowering therapies in patients with elevated triglyceride levels.
Additionally, omega-3-carboxylic acids (Epanova) have been approved by the US Food and Drug Administration based on the EVOLVE trial, where they lowered TGs and non-HDL-C, 31% and 10%, respectively, in patients with severely elevated triglycerides. 89 STRENGTH is a cardiovascular outcome trial with omega-3-carboxylic acids which has enrolled ≈13 000 patients with hypertriglyceridemia and low HDL and high risk for CVD (NCT02104817).
ASO Targeting ApoCIII
ApoCIII is a lipoprotein present on apoB-lipoproteins regulating TG lipolysis by inhibition of LPL, in addition to inhibiting receptor-mediated reuptake of TG-rich remnants and LDL particles. Heterozygote LOF variants were associated with reduced plasma TG up to 40% and were correlated with a 40% reduction in developing CHD. 81, 90 The aforementioned genetic studies sparked the interest in developing drugs targeting apoCIII. Volanesorsen, a second-generation ASO, has been investigated in multiple trials as reviewed by Schmitz and Gouni-Berthold. 91 It reduced TGs up to 77% in a phase III trial of hypertriglyceridemic patients, including 5 patients with familial chylomicronemia syndrome (NCT02300233). It was well tolerated in short-term administration yet it induced mild to severe thrombocytopenia by 2.8-fold in number of patients. 92, 93 Due to this adverse effect, the US Food and Drug Administration decided in May 2018 to reject the approval of Volanesorsen. Another phase I/II trial for N-acetylgalactosamine-conjugated antisense compound AKCEA-APOCIII-L Rx , specially designed for facilitating liver uptake, illustrated promising results with reducing apoCIII and TG up to 91% and 71%, respectively. 94 Based on these promising results, a phase II trial was initiated in 2018. 95 
Conclusion
Unequivocal evidence exists that LDL-C-lowering therapies reduce the risk for ASCVD in proportion to the duration of therapy and the achieved LDL-C reductions. Several therapeutic options have emerged in recent years that hold substantial promise to reduce the global burden of ASCVD further. These therapies can produce unprecedented LDL-C reductions, and infrequent dosing regimens of therapies such as inclisiran could overcome challenges related to poor adherence. In addition to LDL-C lowering, substantial progress is made in the development of therapies targeting Lp(a) and TRLs.
Studies of individuals with monogenic lipid disorders, as well as Mendelian randomization studies, have fueled these developments from discovery of novel lipid genes to informing the design of RCTs. Two of the most exciting developments are the notion that "the lower the better" in LDL-C reduction is directly correlated to a better attenuation of ASCVD and the advent of RCTs that were explicitly designed to test the causality of triglycerides in ASCVD. These efforts are likely to yield novel therapies that will help physicians to bring their dyslipidemic patients to target, to reduce their risk of ASCVD, both in primary as well as in secondary prevention.
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